Landiolol for managing atrial fibrillation in intensive care.

S Rehberg, M Joannidis, T Whitehouse, A Morelli

Research output: Contribution to journalArticle


Landiolol is an injectable ultrashort acting beta-blocker with high beta1 selectivity indicated for heart rate control of atrial fibrillation in the emergency and critical care setting. Accordingly, landiolol is associated with a significantly reduced risk of arterial hypotension and negative inotropic effects. Based on this particular profile along with the clinical experience in Japan for more than a decade landiolol represents a promising agent for the management of elevated heart rate and atrial fibrillation in intensive care patients even with catecholamine requirements. This article provides a review and perspective of landiolol for heart rate control in intensive care patients based on the current literature.
Original languageEnglish
Pages (from-to)A15-A18
JournalEuropean heart journal supplements : journal of the European Society of Cardiology
Issue numberA
Publication statusPublished - Jan 2018


Dive into the research topics of 'Landiolol for managing atrial fibrillation in intensive care.'. Together they form a unique fingerprint.

Cite this